| DUR | drug use review; drug utilization review |
|---|---|
| MEDPAR | Medical Provider Analysis and Review; Medicare Provider Analysis and Review |
| PRC | packed red cells; peer review committee; phase response curve; plasma renin concentration; professio... |
| SR | 1) Sinus Rhythm 2) Sedimentation Rate; 침강 속도 =... |
| ACURP | American College of Utilization Review Physicians |
| professional review organizations | Organizations representing designated geographic areas which have contracts under the pro program to review the medical necessity, appropriateness, quality, and cost-effectiveness of care received by medicare beneficiaries. Peer review improvement act, pl 97-248, 1982. (12 Dec 1998) |
|---|---|
| scientific integrity review | Designation for reports by the united states office of research integrity, identifying questionable research published in articles or books. Notification of the questionable data is carried in the nih guide for grants and contracts. (12 Dec 1998) |
| drug utilization review | Formal programs for assessing drug prescription against some standard. Drug utilization review may consider clinical appropriateness, cost effectiveness, and, in some cases, outcomes. Review is usually retrospective, but some analysis may be done before drugs are dispensed (as in computer systems which advise physicians when prescriptions are entered). Drug utilization review is mandated for medicaid programs beginning in 1993. (12 Dec 1998) |
| insurance claim review | Review of claims by insurance companies to determine liability and amount of payment for various services. The review may also include determination of eligibility of the claimant or beneficiary or of the provider of the benefit; determination that the benefit is covered or not payable under another policy; or determination that the service was necessary and of reasonable cost and quality. (12 Dec 1998) |
| utilization review | An organised procedure carried out through committees to review admissions, duration of stay, professional services furnished, and to evaluate the medical necessity of those services and promote their most efficient use. (12 Dec 1998) |
| aids vaccines | Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent aids. Some vaccines containing antigens are recombinantly produced. (12 Dec 1998) |
| bacterial vaccines | Suspensions of attenuated or killed bacteria administered for the prevention or treatment of infectious bacterial disease. (12 Dec 1998) |
| cancer vaccines | Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumour cells as the source of antigens, or using tumour-specific antigens, often recombinantly produced. (12 Dec 1998) |
| vaccines | Vaccines are microbial preparations of killed or modified microorganisms which can stimulate an immune response in the body in order to prevent future infection with similar microorganism. The smallpox vaccine has totally eliminated the smallpox disease from our planet. (12 Dec 1998) |
| vaccines, attenuated | Live vaccines prepared from microorganisms which have undergone physical adaptation (e.g., by radiation or temperature conditioning) or serial passage in laboratory animal hosts or infected tissue/cell cultures, in order to produce avirulent mutant strains capable of inducing protective immunity. (12 Dec 1998) |
| vaccines, combined | Two or more vaccines in a single dosage form. (12 Dec 1998) |
| vaccines, conjugate | Semisynthetic vaccines consisting of polysaccharide antigens from microorganisms attached to protein carrier molecules. The carrier protein is recognised by macrophages and T-cells thus enhancing immunity. Conjugate vaccines induce antibody formation in people not responsive to polysaccharide alone, induce higher levels of antibody, and show a booster response on repeated injection. (12 Dec 1998) |
| vaccines, DNA | Recombinant DNA vectors encoding antigens administered for the prevention or treatment of disease. The host cells take up the DNA, express the antigen, and present it to the immune system in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigens. The vector is called naked DNA because there is no need for complex formulations or delivery agents; the plasmid is injected in saline or other buffers. (12 Dec 1998) |
| vaccines, inactivated | Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins. (12 Dec 1998) |
| vaccines, synthetic | Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified. (12 Dec 1998) |